Ruxolitinib

INCB018424 (Ruxolitinib) is an orally bioavailable JAK inhibitor with potential antineoplastic and immunomodulating activities. INCB018424 (Ruxolitinib), a characterized JAK1/JAK2 inhibitor (IC50 values for JAK1, JAK2 and JAK3 are 3, 5 and 332 nM, respectively), has reached clinical trials for oncology indications, rheumatoid arthritis, and psoriasis. This compound is worth noting due to its opposite potency profile in the inhibition of the JAK enzymes when compared to CP-690,550.